HDAC6 inhibitors (ACY-1215, CAY10603, and tubastatin A) enhance the sensitivity of glioblastoma cells to TMZ by increasing the levels of DNA mismatch repair proteins such as mutS homolog 2 (MSH2) and MSH6 [59]. The gene discussed is HDAC6; the disease is glioblastoma.